Picture loading failed.

Anti-Influenza A HA therapeutic antibody (Pre-made Gedivumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

39.29 (gedivumab) is fully human neutralizing monoclonal antibody against influenza A. 39.29 is a neutralizing monoclonal antibody that recognizes the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-238-1mg 1mg 3090
GMP-Bios-ab-238-10mg 10mg 21890
GMP-Bios-ab-238-100mg 100mg 148000
GMP-Bios-ab-238-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-Influenza A HA therapeutic antibody (Pre-made Gedivumab biosimilar,Whole mAb)
INN Name Gedivumab
TargetInfluenza A HA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4kvn:HL
Year Proposed2016
Year Recommended2017
CompaniesGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedInfluenza A virus infections
Development Techna